Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

VOLUNTARY ANNOUNCEMENT – UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS

HUA MEDICINE ANNOUNCES ADDITIONAL DATA IN ß-CELL FUNCTION

This announcement is made by Hua Medicine (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business updates of the Group.

The Company is pleased to announce the post-analysis results from dorzagliatin's 24-week monotherapy trial SEED (also known as HMM0301). The following findings were digitally presented in the oral and symposium presentations at the 80th Scientific Session of the American Diabetes Association.

- Fast on-set of action (effective HbA1c reduction in four weeks)
- Significant improvement of -cell function in treatment group as compared to the placebo group
- Significant reduction of two-hour post-prandial glucose reduction was observed in treatment group as compared to the placebo group
- Good safety profile and tolerance of dorzagliatin with limited hypoglycemia and similar incidence of adverse events between the treatment and placebo groups
- Sustained efficacy over 24 weeks
- Good response rate

About Dorzagliatin

Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 Diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 Diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine

Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance